Jessica Hagen
The company was sold to an affiliate of New Enterprise Associates and a consortium of investors for $1.465 billion and ceased trading on the NYSE on Oct. 2.
The launch comes a day after General Catalyst CEO Hemant Taneja announced the closing of the firm’s $485 million acquisition of Ohio healthcare system Summa Health.
The funds will be used to expand the company's workforce and accelerate development of its AI-powered patient engagement platform, Assort OS.
Thanks to the deal, Pfizer will avoid upcoming U.S. tariffs on overseas-made drugs for three years by offering discounted medications directly to American consumers.
The partners will study the effectiveness of SpotitEarly's breath-based test for detecting early-stage breast cancer.
The company will trial its AI eye-tracking technology in Antarctica to simulate the harsh conditions of deep space missions.
The company will adapt space-tested health technologies for Earth, including post-operative recovery kits, civilian spaceflight medical systems and longevity medicine tools.
The company will use the funds to scale nationally, broaden partnerships with payers and health systems, and expand into new neurological condition areas.
Telehealth company Caregility, hybrid cancer care company Daymark Health and virtual care company AmplifyMD also garnered funding.
The company will use the funds to expand Dreem Health, scale nationwide and advance its FDA-cleared sleep apnea technology.